165 related articles for article (PubMed ID: 9792159)
1. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.
Tempfer C; Hefler L; Heinzl H; Loesch A; Gitsch G; Rumpold H; Kainz C
Br J Cancer; 1998 Oct; 78(8):1108-12. PubMed ID: 9792159
[TBL] [Abstract][Full Text] [Related]
2. M3/M21 serum levels in women with adnexal masses and inflammatory diseases.
Hefler L; Tempfer C; Heinzl H; Haeusler G; Steindl P; Schneeberger C; Gitsch G; Kainz C
Int J Cancer; 1998 Aug; 79(4):434-8. PubMed ID: 9699539
[TBL] [Abstract][Full Text] [Related]
3. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
4. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Int J Gynecol Cancer; 2001; 11(4):277-82. PubMed ID: 11520365
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1 and Placental Growth Factor as Screening Markers for Endometriosis.
Cho HY; Kyung MS
Med Sci Monit; 2019 Feb; 25():1087-1092. PubMed ID: 30737365
[TBL] [Abstract][Full Text] [Related]
7. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
8. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer.
Niklinski J; Burzykowski T; Niklinska W; Laudanski J; Chyczewski L; Rapellino M; Furman M
Eur Respir J; 1998 Dec; 12(6):1424-8. PubMed ID: 9877503
[TBL] [Abstract][Full Text] [Related]
9. Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
Reiser E; Aust S; Seebacher V; Reinthaller A; Helmy-Bader S; Schwameis R; Grimm C; Polterauer S
Gynecol Oncol; 2017 Dec; 147(3):690-694. PubMed ID: 28935270
[TBL] [Abstract][Full Text] [Related]
10. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer.
Wu HH; Wang PH; Yeh JY; Chen YJ; Yen MS; Huang RL; Tsai YJ; Yuan CC
Taiwan J Obstet Gynecol; 2014 Mar; 53(1):30-4. PubMed ID: 24767643
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Management of Adnexal Masses.
Biggs WS; Marks ST
Am Fam Physician; 2016 Apr; 93(8):676-81. PubMed ID: 27175840
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
14. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations.
Callet N; Cohen-Solal Le Nir CC; Berthelot E; Pichon MF
Eur J Gynaecol Oncol; 1998; 19(1):50-6. PubMed ID: 9476060
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
[TBL] [Abstract][Full Text] [Related]
16. Cyfra 21-1, a new marker of lung cancer.
Grenier J; Pujol JL; Guilleux F; Daures JP; Pujol H; Michel FB
Nucl Med Biol; 1994 Apr; 21(3):471-6. PubMed ID: 9296767
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.
Uenishi T; Kubo S; Hirohashi K; Tanaka H; Shuto T; Yamamoto T; Nishiguchi S
Br J Cancer; 2003 Jun; 88(12):1894-9. PubMed ID: 12799633
[TBL] [Abstract][Full Text] [Related]
18. Cyfra 21-1 as a marker of lung cancer.
Kinoshita M; Watanabe H; Ichiki M; Sumita S; Okubo Y; Matsunami M; Furuno H; Shiraishi T; Rikimaru T; Oizumi K
Kurume Med J; 1998; 45(1):7-9. PubMed ID: 9658744
[TBL] [Abstract][Full Text] [Related]
19. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
20. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N
Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
